Published in J Urol on August 15, 2012
Investigating urachal carcinoma for more than 15 years. Oncol Lett (2014) 0.91
Combined modalities treatment of pulmonary metastasis from an urachal adenocarcinoma. Rare Tumors (2013) 0.82
Response to targeted therapy in urachal adenocarcinoma. Rare Tumors (2014) 0.79
Surgical treatment of recurrent urachal carcinoma with liver metastasis: a case report and literature review. World J Surg Oncol (2016) 0.75
Urachal carcinoma: Report of two cases and review of the literature. Mol Clin Oncol (2016) 0.75
Genetics and biological markers in urachal cancer. Transl Androl Urol (2016) 0.75
An unusual long-term survey of a patient with widespread malignant urachal tumor, not given chemotherapy or radiotherapy. Case Rep Radiol (2015) 0.75
Belly button piercings: a saving grace? A patent urachus presenting in a 17-year-old girl. BMJ Case Rep (2014) 0.75
Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. Oncotarget (2016) 0.75
National Incidence, Management and Survival of Urachal Carcinoma. Rare Tumors (2016) 0.75
Urachal Tumor: A Case Report of an Extremely Rare Carcinoma. Case Rep Pathol (2017) 0.75
Urachal Carcinoma with Choroidal, Lung, Lymph Node, Adrenal, Mammary, and Bone Metastases and Peritoneal Carcinomatosis Showing Partial Response after Chemotherapy Treatment with a Modified Docetaxel, Cisplatin and 5-Fluorouracil Regimen. Case Rep Oncol (2016) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol (2006) 8.78
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med (2011) 6.34
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol (2011) 5.59
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol (2009) 3.69
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol (2003) 3.52
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood (2010) 3.21
Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology (2011) 3.04
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology (2011) 2.92
The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol (2009) 2.92
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol (2004) 2.82
MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol (2008) 2.77
MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol (2008) 2.76
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res (2007) 2.63
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology (2012) 2.47
Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol (2010) 2.46
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol (2009) 2.17
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol (2006) 2.14
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
A case of abiraterone acetate withdrawal. Eur Urol (2013) 2.06
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Urinary markers in bladder cancer. Eur Urol (2007) 1.95
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology (2007) 1.92
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol (2011) 1.90
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology (2005) 1.82
Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet (2012) 1.81
Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood (2011) 1.79
Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn (2003) 1.78
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76
Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol (2010) 1.74
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med (2015) 1.70
Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer (2005) 1.69
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res (2007) 1.68
In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol (2011) 1.68
Posterior tibial nerve stimulation in the treatment of urge incontinence. Neurourol Urodyn (2003) 1.67
Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol (2012) 1.66
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol (2011) 1.63
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol (2010) 1.63
Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology (2004) 1.62
The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health (2010) 1.62
Survival after treatment for carcinoma invading bladder muscle: a Dutch population-based study on the impact of hospital volume. BJU Int (2011) 1.60
Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol (2011) 1.60
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol (2006) 1.56
Ultrasound detection of rotator cuff tears: observer agreement related to increasing experience. AJR Am J Roentgenol (2010) 1.54
Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol (2009) 1.54
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol (2006) 1.51
Prostate-sparing cystectomy: long-term oncological results. BJU Int (2009) 1.51
Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol (2007) 1.49
Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex. Clin Chem (2005) 1.48
The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol (2006) 1.45
Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol (2013) 1.44
Familial aggregation of urothelial cell carcinoma. Int J Cancer (2002) 1.43
Posterior tibial nerve stimulation in the treatment of idiopathic nonobstructive voiding dysfunction. Urology (2003) 1.43
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 1.43
Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. BJU Int (2011) 1.42
Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer (2005) 1.41
Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol (2009) 1.41
Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology (2007) 1.39
Developments in intravesical therapy for non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther (2010) 1.37
Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology (2009) 1.34
UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol (2006) 1.32
Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control (2003) 1.32
Leukemia and brain tumors among children after radiation exposure from CT scans: design and methodological opportunities of the Dutch Pediatric CT Study. Eur J Epidemiol (2014) 1.30
Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol (2004) 1.30
Risk factors for hypospadias. Eur J Pediatr (2006) 1.27
Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol (2008) 1.26
IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys (2006) 1.26
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Prostate cancer: local staging at 3-T endorectal MR imaging--early experience. Radiology (2005) 1.25
Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst (2011) 1.23
Common variants in DGKK are strongly associated with risk of hypospadias. Nat Genet (2010) 1.23